Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06007547 · ClinicalTrials.gov registry record · Phase 4
Prophylactic Minimally Invasive Surfactant Evaluation
A Phase 4 study of Premature Birth and Respiratory Distress Syndrome, Newborn, sponsored by Endeavor Health.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06007547 is a Phase 4 study of Premature Birth and Respiratory Distress Syndrome, Newborn that is actively recruiting participants, run by Endeavor Health. The registered enrollment target is 200 participants, below the 389-participant average among 38 other Premature Birth trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06007547, a Phase 4 study of Premature Birth and Respiratory Distress Syndrome, Newborn, is actively recruiting participants, sponsored by Endeavor Health.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to explore the question: Does prophylactic administration of exogenous surfactant in the delivery room, using a minimally-invasive technique, improve outcome in preterm infants 22-29 weeks' gestation compared to rescue treatment using the same technique?
Conditions Studied
Interventions
- DRUG Poractant Alfa
Study Locations (1)
Illinois
- Northshore University Healthsystem - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-01-01 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06007547
The ClinicalTrials.gov registry entry for NCT06007547 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 389-participant average among 38 other Premature Birth trials with a reported enrollment target (49% lower). The listed sponsor is Endeavor Health, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Premature Birth appearing as the primary indexed condition, and to 1 intervention - of which Poractant Alfa is the first listed.
NCT06007547 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06007547 about?
NCT06007547 is a clinical study titled "Prophylactic Minimally Invasive Surfactant Evaluation". The purpose of this study is to explore the question: Does prophylactic administration of exogenous surfactant in the delivery room, using a minimally-invasive technique, improve outcome in preterm infants 22-29 weeks' gestation compared to rescue treatment using the same technique?
What is the current status of trial NCT06007547?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2024-01-01. Estimated completion is 2027-07-31.
What conditions does trial NCT06007547 study?
This clinical trial studies the following conditions: Premature Birth, Respiratory Distress Syndrome, Newborn.
What interventions are being tested in trial NCT06007547?
The interventions under investigation include: Poractant Alfa (DRUG).
Who is sponsoring clinical trial NCT06007547?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06007547 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Premature Birth
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Outpatient Antibiotics Following Previable Rupture of Membranes (pPPROM) Between 18 0/7 and 22 6/7 Weeks Gestational Age
RECRUITING · Phase 4
-
A Randomized Controlled Trial of Impact of Wearable, Wireless Breast Pumps on Frequency and Efficacy of Milk Expression in Mothers of Premature Infants
RECRUITING · NA
-
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
RECRUITING · NA
-
The Periviable GOALS Decision Support Tool
RECRUITING · NA
-
Postpartum Care in the NICU (PeliCaN) Transitions
RECRUITING · NA
-
Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.